NHS DUMFRIES & GALLOWAY

DRAFT FINANCIAL LDP

Davianua	O 11441146	Ctotomon	•
revenue	Oullum	Statemen	14

	2014-15		I	2015-16			2016-17			2017-18			2018-19			2019-20	
			Rec	Non-Rec		Rec	Non-Rec		Rec	Non-Rec		Rec					
Line no	Total		£000s	£000s	TOTAL	£000s	£000s	TOTAL	£000s	£000s	TOTAL	£000s	£000s	TOTAL	£000s	£000s	TOTAL
		Total Expenditure															
1.01	150,661	Clinical Service - Pay	152,697	3,607	156,304	154,914	1,888	156,802	155,444	6,035	161,479	157,380	3,551	160,932	159,814	1,151	160,965
1.02	178,555	Clinical Service - Non-Pay	161,691	4,713	166,404	164,828	1,101	165,929	169,298	11,094	180,392	171,092	5,575	176,667	173,314	5,608	178,922
1.03	7,284	Non-Clinical Service - Pay	8,525	175	8,700	8,589	92	8,681	8,577	293	8,870	8,532	274	8,806	8,638	134	8,771
1.04	8,636	Non-Clinical Service - Non-Pay	6,283	229	6,512	6,206	74	6,280	6,131	10,072	16,203	6,022	17,492	23,514	6,064	17,484	23,549
1.05	0	Outgoing funds - Health & Social Care Integration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.06	345,137	Total Gross Expenditure	329,195	8,724	337,919	334,537	3,155	337,692	339,450	27,494	366,944	343,026	26,893	369,919	347,830	24,377	372,207
		Less															
1.07	18,480	Operating Income	16,722	0	16,722	16,722	0	16,722	16,722	0	16,722	16,722	0	16,722	16,722	0	16,722
1.08	0	Incoming funds - Health & Social Care Integration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.09	18,480	Total Gross Income	16,722	0	16,722	16,722	0	16,722	16,722	0	16,722	16,722	0	16,722	16,722	0	16,722
1.10	326,657	Total Expenditure	312,473	8,724	321,197	317,815	3,155	320,970	322,728	27,494	350,222	326,304	26,893	353,197	331,108	24,377	355,485
1.11	25,996	Total Non-Core RRL Expenditure (line 7.12)	n/a	9,120	9,120	n/a	5,598	5,598	n/a	17,322	17,322	n/a	11,549	11,549	n/a	12,166	12,166
1.12	15,431	FHS Non Discretionary Net Expenditure	15,583	0	15,583	15,737	0	15,737	15,892	0	15,892	16,049	0	16,049	16,049	0	16,049
		Core RRL Expenditure															
1.13	285,230	Core Revenue Resource Outturn	296,890	(396)	296,494	302,078	(2,443)	299,635	306,836	10,172	317,008	310,255	15,344	325,599	315,059	12,211	327,270
1.14	287,230	Core Revenue Resource Limit (RRL) (line 1.24)	297,411	(917)	296,494	302,410	(2,775)	299,635	307,400	9,608	317,008	311,465	14,134	325,599	316,714	10,556	327,270
1.15	2,000	Saving / (Excess) against Core RRL	521	(521)	(0)	332	(332)	0	564	(564)	0	1,210	(1,210)	0	1,655	(1,655)	0

				ŀ	Recurring a	nd Non-Re	curring Cor	e Revenue I	Resource L	imit Project	ion						
	2014-15 Total		Rec	2015-16 Non-Rec		Rec	2016-17 Non-Rec		Rec	2017-18 Non-Rec		Rec	2018-19 Non-Rec		Poo	2019-20 Non-Rec	
Line no			£000s	£000s	TOTAL	£000s	£000s	TOTAL	£000s	£000s	TOTAL	£000s	£000s	TOTAL	£000s	£000s	TOTAL
1.16	259,723	Baseline allocation	267,281	n/a	267,281	272,193	n/a	272,193	277,043	n/a	277,043	280,909	n/a	280,909	285,958	n/a	285,958
1.17	416	Anticipated allocations - recurring (line 5.57)	0	n/a	0	0	n/a	0	0	n/a	0	0	n/a	0	0	n/a	0
1.18	260,139	Updated baseline	267,281	n/a	267,281	272,193	n/a	272,193	277,043	n/a	277,043	280,909	n/a	280,909	285,958	n/a	285,958
1.19		Carry forward	n/a	2,000	2,000	n/a	0	0	n/a	4,000	4,000	n/a	3,000	3,000	n/a	0	0
1.20	(4,322)	Transfer of depreciation / amortisation (line 7.02)	n/a	(4,450)	(4,450)	n/a	(4,045)	(4,045)	n/a	(5,069)	(5,069)	n/a	(7,196)	(7,196)	n/a	(7,813)	(7,813)
1.21		Revenue transferred to capital	n/a	0	0	n/a	0	0	n/a	0	0	n/a	0	0	n/a	0	0
1.22	31,413	Anticipated allocations - earmarked / non-rec (line 5.57)	30,130	1,533	31,663	30,217	1,270	31,487	30,357	10,677	41,034	30,556	18,330	48,886	30,756	18,369	49,125
1.23	27,091	Sub-total	30,130	(917)	29,213	30,217	(2,775)	27,442	30,357	9,608	39,965	30,556	14,134	44,690	30,756	10,556	41,312
1.24	287,230	Core Revenue Resource Limit (RRL)	297,411	(917)	296,494	302,410	(2,775)	299,635	307,400	9,608	317,008	311,465	14,134	325,599	316,714	10,556	327,270

Main contact name	Kelly McClure
email address	kelly.mcclure@nhs.net
Phone number	01387 244020

Version number	
Date of submission	
Time	

Board Approval Date

								NHS DI	JMFRIES & G	ALLOWAY												
								D	RAFT FINANCI	AL LDP												
								B	fficiency Sav	ings												
			2015-16			Risk	rating			2016-17			Risk	rating			2017-18			Risk	rating	
Line no	Saving Scheme Details	Rec £000s	Non-Rec £000s	Total £000s	Unidenti fied	High	Med	Low	Rec £000s	Non-Rec £000s	Total £000s	Unidenti fied	High	Med	Low	Rec £000s	Non-Rec £000s	Total £000s	Unidenti fied	High	Med	Low
	Efficiency & Productivity Workstreams				%	%	%	%				%	%	%	%				%	%	%	%
2.01	Service productivity	2,172	300	2,472	n/a	16%	30%	54%	1,000		1,000	n/a	100%		0%	1,000		1,000	n/a	100%		0%
	Drugs and prescribing	1,639		1,639	n/a	18%	41%	41%	2,000	ļ	2,000	n/a	25%	60%	15%	2,000		2,000	n/a	30%	60%	10%
	Procurement	645	35	680	n/a	0%	57%	43%	300	.	300	n/a		35%	65%	300		300	n/a		35%	65%
	Workforce	880	510	1,390	n/a	14%	73%	13%	500	l	500	n/a	50%	50%	0%	500		500	n/a	50%	50%	0%
2.05	Shared HR			0	n/a			100%		.	0	n/a			100%		.	0	n/a			100%
2.06	services Facilities			0	n/a			100%			0	n/a			100%			0	n/a			100%
2.07	Other shared services			0	n/a			100%		ļ	0	n/a			100%			0	n/a			100%
	Support services (non-clinical)	70	100	170	n/a		88%	12%		ļ	0	n/a			100%			0	n/a			100%
	Estates and facilities	433	100	533	n/a	11%	38%	51%			0	n/a			100%			0	n/a		ļl	100%
	Unidentified savings	1,076		1,076	100%	n/a	n/a	n/a	4,310		4,310	100%	n/a	n/a	n/a	4,450		4,450	100%	n/a	n/a	n/a
2.11	Total In-Year Efficiency Savings	6,915	1,045	7,960	1,076	946	3,168	2,771	8,110	0	8,110	4,310	1,750	1,555	495	8,250	0	8,250	4,450	1,850	1,555	395
				•													•					
2.12	Cash-releasing Savings	6,455	1,045	7,500					7,500		7,500					7,500		7,500				
	Productivity Savings (non-cash)	460		460					610		610					750		750				
2.14	Total In-Year Efficiency Savings (must match line 2.11)	6,915	1,045	7,960					8,110	0	8,110					8,250	0	8,250				

					Effici	ency Sa	avings										
ine		Saving Scheme Details	Rec	2018-19 Non-Rec		l loci de seti	Risk r			Rec	2019-20 Non-Rec		Risk rating				
no			£000s	£000s	Total £000s	Unidenti fied	High	Med	Low	£000s	£000s	Total £000s	Unidenti fied	High	Med	Low	
	Efficiency	v & Productivity Workstreams				%	%	%	%				%	%	%	%	
2.15	Service pr	oductivity	1,000		1,000	n/a	100%		0%	1,000		1,000	n/a	100%		0%	
2.16	Drugs and	prescribing	1,000		1,000	n/a	30%	60%	10%	1,000		1,000	n/a	30%	65%	5%	
2.17	Procureme	ent	300		300	n/a	10%	25%	65%	300		300	n/a	10%	25%	65%	
2.18	Workforce		1,000		1,000	n/a	100%		0%	1,000	_	1,000	n/a	100%		0%	
2.19	Shared	HR			0	n/a			100%			0	n/a			100%	
2.20	services	Facilities			0	n/a			100%			0	n/a			100%	
2.21		Other shared services			0	n/a			100%		l	0	n/a			100%	
2.22	Support se	ervices (non-clinical)			0	n/a			100%			0	n/a			100%	
2.23	Estates ar	nd facilities			0	n/a			100%			0	n/a			100%	
2.24	Unidentifie	ed savings	5,100		5,100	100%	n/a	n/a	n/a	5,252		5,252	100%	n/a	n/a	n/a	
2.25	Total In-Y	ear Efficiency Savings	8,400	0	8,400	5,100	2,330	675	295	8,552	0	8,552	5,252	2,330	725	245	
			-														
2.26	Cash-relea	asing Savings	7,500		7,500					7,500		7,500					
		y Savings (non-cash)	900		900					1,052	Ι	1,052					
2.28	Total In-Y	ear Efficiency Savings (must match line 2.25)	8,400	0	8,400					8,552	0	8,552					

NHS DUMFRIES & GALLOWAY


DRAFT FINANCIAL LDP

Financial Trajectories

	Revenue Outturn	
	Saving / (Excess) against Core RRL as at the end of:	£000s
3.01	Jun	350
3.02	Jul	450
3.03	Aug	500
3.04	Sep	550
3.05	Oct	650
3.06	Nov	750
3.07	Dec	675
3.08	Jan	550
3.09	Feb	300
3.10	Mar	(0)

Efficiency Savings Cumulative efficiency savings as at the end of:	Total Savings £000s
Jun	914
Jul	1,295
Aug	1,752
Sep	2,323
Oct	2,971
Nov	3,732
Dec	4,685
Jan	5,713
Feb	6,817
Mar	7,960





							NHS DUN	IFRIES & GALLOWAY
							Financial I	Planning Assumptions
Line no	2014-15	Assumptions - uplift	(%)	2015-16	2016-17	2017-18	2018-19	2019-20
4.01 4.02 4.03	2.50% 0.00% 0.00%	Resources	Base uplift NRAC Other	1.80% 0.00% 0.00%	1.80% 0.00% 0.00%	1.80% 0.00% 0.00%	1.80% 0.00% 0.00%	1.80% 0.00% 0.00%
4.04 4.05	1.00% 1.41%	Pay	Base uplift Incremental o	1.00% 1.10%	1.00% 1.04%	1.00% 0.83%	1.00% 0.81%	1.00% 0.78%
4.06 4.07	0.00%	Prices	Other	0.00%	0.00%	0.00%	0.00%	0.00% 2.00%
4.08 4.09	2.60% 2.50%	GP prescribing	Price Volume	3.70% 3.20%	2.20% 2.80%	2.20% 2.80%	2.20% 2.80%	2.20% 2.80%
4.10 4.11	6.00% 9.40%	Hospital drugs	Price Volume	8.70% 2.50%	10.40% 2.70%	9.30% 2.00%	8.20% 2.00%	<u>8.20%</u> 2.00%
4.12 4.13 4.14			General Den General Den General Oph	1.00% 1.00% 1.00%	1.00% 1.00% 1.00%	1.00% 1.00% 1.00%	1.00% 1.00% 1.00%	1.00% 1.00% 1.00%
4.15			Pharmaceuti	1.00%	1.00%	1.00%	1.00%	1.00%

[Risk Assessment
	Key Assumptions / Risks	Risk rating (please select from drop- down)	Impact / £
4.16			
	Allocation Uplift	High Risk	ty 2015/16 uplift has been confirmed by the Scottish Government todate. The plan assumes the same % uplift over years 2-5 which can not be assessed with any certainty at this moment in tim
4.17	CRES Delivery	High Risk	ng upon the workshops already undertaken this year to identify savings plans, further reviews and meetings are planned to continue to monitor progress against the plan. 2015/16 represents an
4.18	Prescribing (General)	High Risk	s to continue to deliver this level of saving are not as robust as in the past. Whilst the plan has assesed the on-going financial risks of new drugs and increasing growth (taking into account nation
4.19	Prescribing - New Medicines Fund	High Risk	An assessment has been undertaken with in the plan to incorporate estimates of likely growth of drugs in this area. It is assumed that these will be matched with funding within the 5 year plan.
4.20	Workforce/Recruitment	High Risk	20% of our consultant workforce remains covered by high-cost locum posts. Whilst appropriate provision has been made in the financial plan (£4m NR) to continue to absorb these costs, this is
4.21	Health and Social Care Integration	High Risk	or supporting and resourcing the implementation within the allocation identified going forward. NHS D&G has made good progress with Council Colleagues in recent months in progressing H&S
4.23	DGRI Maintenance	High Risk	RI will continue to be a risk and require expenditure in the period that the hospital remains operational. The resources available to fund backlog maintenance are severely restricted and areas of
4.24	Externals (OOA SLAs)	High Risk	stantial increase in activity undertaken outwith Board boundaries. Whilst financial provision has been made in the plan, changes relating to service redesign (particularly across Vascular and Car
4.25	Earmarked Recurring Allocations		rring allocations will continue to be highlighted as a risk when assessing the recurrent nature of funding. These are continuously reviewed and where risks are highlighted funding is only released
4.26	Inflation Uplifts		indepth review of historic trends, combined with best available knowledge has been modelled in determining projected increases. Information has been shared and discussed with colleagues a
4.27	Developments and Cost Pressures Pay Inflation/Incremental Drift	Medium Risk Medium Risk	um of £3m and a non-recurring sum of £8.8m for 2015/16 has been set aside to cover the costs of future regional and national developments, cost pressures and any other critical or must do d Robust financial planning information exists to allow accurate estimates of basic pay settlements for 2015/16 and beyond (based upon current assumptions of 1% pay awards).
4.28	Statutory Change/Changes to legislation		tory compliance in relation to VAT/ NI and pensions. Any future changes to current regulations and compliance would impact on the overall financial plan. These are reviewed regularly by the ce
4.29	DGRI Funding for NPD	Medium Risk	Availability of bank lending to support new DGRI via NPD procurement link with SFT re. mitigation of risk. Risk will reduce as the project progresses towards financial close.
4.30	Clinical Change Programme	High Risk	o reduce the financial risk of developing the new DGRI, the scale of the clinical change programme required to bring about the necessary transformation in service delivery reflect a significant ris
4.31	Capital Receipts	Medium Risk	Funding from retained receipts in future years is not guaranteed. The Capital Plan assumes this will be agreed in order for associated programmes of work to commence.
4.32	Carry Forward	Low Risk	d in 2015/16 in support of the planning of the new hospital. The retained carry-forward of £7m from prior years is banked for future double running and associated costs of the new hospital. This

					NH	S DUMFI	RIES & G	ALLOWA	Y													
				Rev	enue Re	source Li	imit - Ant	icipated A	Allocation	S												
				201	5-16		r	201	6-17			2017	-18			201	8-19			201	9-20	
Anticipated Allocations	Directorate	SG Contact Name	Recurring £000s	Earmarked £000s		TOTAL	Recurring £000s	Earmarked £000s		TOTAL	Recurring £000s	Earmarked £000s		TOTAL	Recurring £000s	Earmarked £000s	Non-Rec £000s	TOTAL	Recurring £000s	Earmarked £000s	Non-Rec £000s	τοτ
Brokerage Repayments	Health Finance, eHealth & Pharmaceuticals	Robert Peterson				0				0				0				0				0
eHealth Bundle	Health Finance, eHealth & Pharmaceuticals	Lesly Donovan	0	1,459	818	2,277	0	1,459	800	2,259	0	1,459	800	2,259	0	1,459	800	2,259	0	1,459	800	2,2
Effective Prevention Bundle	The Quality Unit	Andy Bruce		1,056		1,056		1,056		1,056		1,056		1,056		1,056		1,056		1,056		1,0
Dental Services Bundle	Health & Social Care Integration	Tom Ferris		402		402		402		402		402		402		402		402		402		40
Mental Health Bundle	Health & Social Care Integration	Geoff Huggins		354		354		354		354		354		354		354		354		354		3
HAI Bundle Nursing Bundle	CNO, Patients, Public & Health Professions CNO, Patients, Public & Health Professions	Andrew Wilkinson Susan Malcolm		298 48		298 48	-	298 48		298 48		298 48		298 48		298 48		298 48		298 48		2
PMS Bundle	Health & Social Care Integration	Marlene Walker		48 22,580		48 22,580		48 22,775		48		48 22,972		48 22,972		48 23,171		48 23,171		48 23,371		23,
Maternity Services and Maternal and Infant Nutrition Bundle	Children & Families	Lynne Nicol		134		134		134		134		134		134		134		134		134		1
Alcohol Funding	CMO, Public Health & Sport			1,306		1,306	0	1,306	0	1,306	0	1,306	0	1,306	0	1,306	0	1,306	0	1,306	0	1,3
Drug Treatment Funding	CMO, Public Health & Sport			686		686	0	686	0	686	0	686	0	686	0	686	0	686	0	686	0	6
Equally Well Test Sites	CMO, Public Health & Sport					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Keep Well / Well North	CMO, Public Health & Sport			133		133	0	57	0	57	0		0	0	0	0	0	0	0	0	0	
Research Support and UKCRC Budget	CMO, Public Health & Sport			327		327		327		327		327		327		327		327		327		3
AAA Screening	CMO, Public Health & Sport					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Glasgow Centre for Population Health	CMO, Public Health & Sport					0		0		0		0		0		0		0		0		
Organ Donation Taskforce (NSS)	CMO, Public Health & Sport					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
SNBTS vCJD (NSS)	CMO, Public Health & Sport					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CYP Specialist Services National Delivery Plan (NDP)	Children & Families	Fiona McKinley		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Unscheduled Care	Health Workforce & Performance	Suresh Gajjar		224		224	0	205	0	205	0	205	0	205	0	205	0	205	0	205	0	2
Immunisation programme	CMO, Public Health & Sport	Janet Sneddon			640	640		-	400	400	-		400	400	0	0	400	400	0	0	400	4
IVF Waiting Times Implementation	Children & Families	Lynne Nicol				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Early Years - Family Nurse Partnership	Children & Families	Carolyn Wilson		(474)		0	0	0 (171)	0	0	0	0 (171)	0	0	0	0 (171)	0	0	0	0 (171)	0	
Positron Emission Tomography (PET) SCAN NHS GG&C Emergency Medical Retrieval Services (EMRS)	The Quality Unit The Quality Unit	Rachael Dunk Liz Porterfield		(171)		<u>(171)</u> 0	0	0	0	<u>(171)</u> 0	0	(171)	0	(171) 0	0	0	0	(171) 0	0	0	0	(1
NHS Carer Information Strategies	Health & Social Care Integration	Liz Fonterneid				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Primary Medical Services	Health & Social Care Integration					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Scottish Dental Access Initiative (SDAI)	Health & Social Care Integration					0		0	0	0		Ŭ	0	0		Ŭ		0		Ŭ	0	
NES - Optometry CET & DOCET	Health & Social Care Integration	-				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NES - Aberdeen Dental School	Health & Social Care Integration					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NES - Workforce Psychology Development	Health & Social Care Integration					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	,
Emergency & Access Delivery Team (EADT)	Health & Social Care Integration					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Combat Stress - National Support Services	Health & Social Care Integration					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Salaried General Dental Services	Health & Social Care Integration	Tom Ferris		1,341		1,341		1,341		1,341		1,341		1,341		1,341		1,341		1,341		1,
Distant Islands Allowance	Health Finance, eHealth & Pharmaceuticals					0		0		0		0		0		0		0		0		
Highland and Islands Travel Scheme	Health Finance, eHealth & Pharmaceuticals					0		0		0		0		0		0		0		0		
Island Boards - Partnership Working	Health Finance, eHealth & Pharmaceuticals					0		0		0		0		0		0		0		0		
Golden Jubilee activity	Health Finance, eHealth & Pharmaceuticals			(746)		(746)	0	(746)	0	(746)	0	(746)	0	(746)	0	(746)	0	(746)	0	(746)	0	(7
Stracathro Regional Treatment Centre	Health Workforce & Performance	Suresh Gajjar				0		0		0		0		0		0		0		0		
18 Weeks allocations	Health Workforce & Performance	Suresh Gajjar		70		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	······
Distinction Awards for NHS Consultants	Health Workforce & Performance	Dave McLeod		72		72	0	72	0	72	0	72	0	72	0	72	0	72	0	72 0	0	
Waiting Times - AST allocation Early Detection of Cancer	Health Workforce & Performance	Suresh Gajjar Dr David Linden				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Early Detection of Cancer QUEST Local Quality & Efficiency Support	Health Workforce & Performance Health Workforce & Performance	Calum Wallace				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Modernising Medical Careers (NES)	Health Workforce & Performance	Dave McLeod				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Calman 100 Implementation (NES)	Health Workforce & Performance	Dave McLeod				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	÷
Leadership Programme (NES)	Health Workforce & Performance	John Cowie				Ő	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
National Implementation of eEES - GG&C	Health Workforce & Performance	Dave McLeod				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Police Custody Transfer	Health Finance, eHealth & Pharmaceuticals	Julie McKinney				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
Patients Rights Act - Delivery Support	Health Workforce & Performance	Suresh Gajjar				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Reshaping the Medical Workforce	Health Workforce & Performance	Johann MacDougall				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NDC Top Sliced Contributions	Health Finance, eHealth & Pharmaceuticals	Alan Morrison		(323)		(323)		(323)		(323)		(323)		(323)		(323)		(323)		(323)		(32
NSD Risk Share	Health Finance, eHealth & Pharmaceuticals	Alan Morrison	I	(1,745)		(1,745)	Ι	(1,745)		(1,745)		(1,745)		(1,745)	[(1,745)	[(1,745)	I	(1,745)	[(1,7
Enzyme replacement / orphan drugs	Health Finance, eHealth & Pharmaceuticals	Alan Morrison				0		0		0		0		0		0		0		0		C
Assumed parity uplift to funding (NRAC)	Health Finance, eHealth & Pharmaceuticals	Alan Morrison				0	0			0	0			0	0			0	0			(
Further anticipated allocations (copied from line 6.50)			0	2,695	75	2,770	0	2,682	70	2,752	0	2,682	9,477	12,159	0	2,682	17,130	19,812	0	2,682	17,169	19,8
Total Anticipated Allocations			0	30,130	1,533	31,663		30,217		31,487			10,677	41,034	-	30,556	18,330	48.886		30,756	18,369	49,

								MFRIES															
					Rev	enue Res	ource Li	mit - Furt	her Antic	ipated Al	locations	•											
	Further Anticipated Allocations	Directorate (please select from drop- down)	SG Contact Name		201 Earmarked	Non-Rec			Earmarked				201 Earmarked	Non-Rec		Recurring	201 Earmarked	8-19 Non-Rec		Recurring	201 Earmarked	19-20 d Non-Rec	c
L				£000s	£000s	£000s	TOTAL	£000s	£000s	£000s	TOTAL	£000s	£000s	£000s	TOTAL	£000s	£000s	£000s	TOTAL	£000s	£000s	£000s	; 1
P	Please list further anticpated allocations not included in	Health & Social Care Integration	Sandra Falconer		15		15		15		15		15		15		15		15		15		••••
	Advocacy Provision Community pharmacy practitioner champions	Health Workforce & Performance	Shelagh Scott		15 10	••••••	10		15 10	·····	10		15 10		10	••••••	15 10		10	••••••	15 10	······	
	Health Visitor Support GIRFEC & Early Years	Children & Families	John Froggatt		60		60		60		60		60		60		60		60		60		
	MARS - Multi Agency Resource Service	Health & Social Care Integration	Robert Peterson		(4)		(4)		(4)	1	(4)		(4)		(4)		(4)		(4)		(4)		
	Open University Pre-Reg Nursing Education Programme	Health Workforce & Performance	Susan Malcolm			75	75			70	70			55	55			20	20	[l	20	
	Patient Advice & Support Service (PASS) Top Slice	Health & Social Care Integration	Sandra Falconer		(47)		(47)		(47)		(47)		(47)		(47)		(47)		(47)		(47)		
	Pharmacy pre registration students to NES	ealth Finance, eHealth & Pharmaceutica	Shelagh Scott		(31)		(31)		(31)		<mark>(31)</mark>		(31)		(31)		(31)		(31)		(31)		
	Police Custody and Forensic Medical Services		Julie McKinney		170		170		170		170		170		170		170		170		170	4	
ŀ	CUVC Cratic diag		TRO		(10)		0		(10)	+	0		(10)		0		(10)		0	·	(10)		
ŀ	CHKS Contribution Cochlear Implants		TBC TBC		(19)		(<u>19)</u> 0		(19)	+	(19) 0	0	(19) 0		<mark>(19)</mark> 0	0	(19) 0		<mark>(19)</mark> 0	0	(19)		••••
	aged Diagnostic Networks (MDICN, SBCMDN, SMVN & SR		TBC		(13)		(13)		(13)	+	(13)		(13)		(13)		(13)		(13)		(13)		
10	Molecular Pathology	1	TBC		(10)	••••••		•••••	(10)	••••••	0	0	0		0	0	0		0		0	+	
	Optimal Reprefusion Service to SAS		TBC			••••••	0		0	+	0	0	0		0	0	0		0	0	0		
	Radiotherapy Satellite Project - WoS		TBC		(20)		(20)		(33)		(33)		(33)		(33)		(33)		(33)		(33)	1	
	ScotSTAR transfer to SAS		TBC		(141)		(141)		(141)		(141)		(141)		(141)		(141)		(141)	[(141)		
cir	nes Fund (assumed costs to be funded) (based upon NRA	C for 15-16)	Julie McKinney		2,715		2,715		2,715		2,715		2,715		2,715		2,715		2,715		2,715		
	ASRP Unitary Charge (NPD) New Hospital		Allan Morrison				0		0		0		0	9,422	9,422		0	17,110	17,110		0	17,149	9
							0		0		0		0		0		0		0	ļ	0	4	
							0		0		0		0		0		0		0		0	4	
							0				0				0				0		·····	·	
						••••••	<u>0</u>				0				00		•••••••		0	······	·····	······	••••
						••••••	0			+	0				0	••••••	•••••••		0	••••••	·····	······	••••
						••••••	<u>0</u>	•••••		••••••	0	•••••	•••••		0	••••••	•••••••		0		·····	+	
						••••••	0			+	0		•••••		0				0				
							0				0				0				0		(1	
[0				0				0				0	[l		
							0				0				0				0		ļ		
							0				0				0				0	ļ	ļ		
							0				0				0				0	······	·····	·	·
		•••••••••••••••••••••••••••••••••••••••					0				0				0		•••••••		0		·····		
							<u>0</u>			+	0				0		• • • • • • • • • • • • • • • • • • • •		0				
ŀ							0			+	0				0		+		0				•••••
							0			+	0				0		+		0				
						••••••	0			••••••	0				0		•••••••		0		(·····		
					1		0				0				0		1		0			1	
							0				0				0				0	[l		
							0				0				0				0		ļ		
l							0				0				0				0		ļ		
ŀ							0				0				0				0			4	
ŀ							0				0				0				0		·····		
							0			+	0				0				0		·····		
ŀ							0			+	0				0 0		•••••••		0		·····		
							<u>v</u>			+	0				<u>0</u>		•••••••		0	······	·····	······	•••
-							0			+	0				0		+		0				
ŀ		•									0				0		• • • • • • • • • • • • • • • • • • • •		0	f'	·····		

NHS DUMFRIES & GALLOWAY

Non-Core RRL Expenditure

Line no	2014-15 Total £000s		2015-16 Total Non-Rec £000s	2016-17 Total Non-Rec £000s	2017-18 Total Non-Rec £000s	2018-19 Total Non-Rec £000s	2019-20 Total Non-Rec £000s
		Non-Core RRL Expenditure					
7.01	222	Capital Grants (line 8.102)	369	0	0	0	0
7.02	4,322	Depreciation / Amortisation	4,450	4,045	5,069	7,196	7,813
		ODEL - IFRS PFI Expenditure					
7.03	170	PFI/PPP/Hub - Depreciation	228	228	928	3,028	3,028
7.04	0	PFI/PPP/Hub - Impairment	1,374		10,000		
7.05	0	PFI/PPP/Hub - Notional Costs	1,374				
7.06	170	Total IFRS PFI Expenditure	2,976	228	10,928	3,028	3,028
		Anually Managed Expenditure					
7.07	21,000	AME - Impairments	1,000	1,000	1,000	1,000	1,000
7.08	100	AME - Provisions	100	100	100	100	100
7.09	182	AME - Donated Assets Depreciation	225	225	225	225	225
7.10	0	AME - Movement in Pension Valuation	0	0	0	0	0
7.11	21,282	Total AME Expenditure	1,325	1,325	1,325	1,325	1,325
7.12	25,996	Total Non-Core RRL Expenditure (copied to line 1.11)	9,120	5,598	17,322	11,549	12,166

		Infrastructure Investment Program	nme				
e No	2014-15 £000s		2015-16 £000s	2016-17 £000s	2017-18 £000s	2018-19 £000s	2019-20 £000s
		Capital Expenditure Property					
001		Statutory compliance and backlog maintenance property expenditure					
02 03	948	Radiotherapy equipment construction works Enabling works for stand alone NPD projects	3,478	26,553	15,428	9,662	2,655
004		Enabling works for hub initiative projects	0,170	20,000	10,120	0,002	2,000
005 006	502 402	Dalbeattie PCC Dunscore PCC					
007	402	Womens & Children Hub	3,143				
800 009	502	Development balance - including property,equipment and IT (split still to be prioritised) Rolling Programme - including property,equipment and IT (split still to be prioritised)	937 1,300	825 1,300	640 1,300	640 1,300	640 1,300
010		Clinical Change Programme	0	2,000	4,000	4,000	4,000
)11)12							
13							
14							
)15)16							
017							
)18)19							
020							
)21)22	2,354	Other Total Property Expenditure	8,858	30,678	21,368	15,602	8,595
	2,001	Equipment	0,000	00,010	21,000	10,002	0,000
	140	Medical Equipment					
)23)24	146	Equipping costs of revenue financed projects Imaging (CT / Ultrasound / MRI / Gamma Cameras)					
025		Other X ray (Angio / Dental / Fluoroscopy / General X Ray)					
)26)27		Radiotherapy PET Replacement Programme					
028		IV systems (Syringe and Volumetric Pumps)					
)29)30	1,237 1,383	Other medical equipment eg defibrilators, dialysis machines, endoscopes Sub-total - Medical Equipment	600 600	1,000 1,000	400 400	1,000 1,000	1,000 1,000
	1,000	Vehicles	000	1,000	100	1,000	1,000
031		Emergency vehicles					
)32)33		Patient Transport Service (PTS) Support services vehicles					
034		Other vehicles					
035	0	Sub-total - Vehicles Other Equipment	0	0	0	0	0
036	0	Plant and machinery					
037 038	64 64	Other Sub-total - Other Equipment	100 100	100 100	100 100	100 100	100 100
039	1,447	Total Equipment Expenditure IM&T Projects	700	1,100	500	1,100	1,100
040	784	e-Health projects	800	800	1,400	800	800
041 042	70	НЕРМА					
043							
044 045							
)45)46							
047 048							
)48)49							
050							
)51)52	0	Other					
053	854	Total IM&T Expenditure	800	800	1,400	800	800
054	0	Other Capital Expenditure Intangible assets					
055		Other					
	0	Total Other Expenditure	0	0	0	0	0
	4,655			32,578	23,268	17,502	10,495
	r	Total Gross Direct Capital Expenditure	10,358		1		
)57		Capital Receipts	10,358				
)57)58	0	Capital Receipts Other capital grants received		(495)	(345)	(200)	(144)
056 057 058 059 060	0 (375)	Capital Receipts	(540)	(495)	(345)	(200)	(144)
)57)58)59)60		Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111)		(495) (495)	(345) (345)	(200) (200)	(144) (144)
)57)58)59)60)61	(375) (375)	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts	(540) (540)	(495)	(345)	(200)	(144)
057 058 059 060	(375)	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061)	(540)				(144)
957 958 959 960 961	(375) (375)	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure	(540) (540)	(495)	(345)	(200)	(144)
957 958 959 960 961 962 963 964	(375) (375) 4,280	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061)	(540) (540) 9,818	(495) 32,083	(345) 22,923	(200) 17,302	(144) 10,351
957 958 959 960 961 962 963 964 965	(375) (375) 4,280	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure	(540) (540) 9,818	(495) 32,083	(345) 22,923	(200) 17,302	(144) 10,351
957 958 959 960 961 962 963 964 965 966	(375) (375) 4,280 222	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure Capital Grants (line 8.102)	(540) (540) 9,818 369	(495) 32,083	(345) 22,923 0	(200) 17,302 0	(144) 10,351 0
957 958 959 960 961 962 963 964 965 966 966	(375) (375) 4,280	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure Capital Grants (line 8.102) Total Indirect Capital Expenditure Total Indirect Capital Expenditure	(540) (540) 9,818 369 369	(495) 32,083	(345) 22,923	(200) 17,302 0 0	(144) 10,351 0
957 958 959 960 961 962 963 964 965 966 966	(375) (375) 4,280 222 222	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure Capital Grants (line 8.102) Total Indirect Capital Expenditure Total Indirect Capital Expenditure Total Net Capital Expenditure (line 8.062 plus line 8.067)	(540) (540) 9,818 369	(495) 32,083 0 0	(345) 22,923 0 0	(200) 17,302 0	(144) 10,351 0
057 058 059 060 061 062 063 064 065 066 067 068	(375) (375) 4,280 222 222	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure Capital Grants (line 8.102) Total Indirect Capital Expenditure Total Indirect Capital Expenditure	(540) (540) 9,818 369 369	(495) 32,083 0 0	(345) 22,923 0 0	(200) 17,302 0 0	(144) 10,351 0
057 058 059 060 061 062 063 064 065 066 067 068	(375) (375) 4,280 222 222 4,502 3,536 (375)	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure Capital Grants (line 8.102) Total Indirect Capital Expenditure Total Indirect Capital Expenditure Total Indirect Capital Expenditure Capital Resource Limit (CRL) SGHSCD formula allocation Asset sale proceeds reapplied (net book value)	(540) (540) 9,818 369 369 10,187 3,840 (540)	(495) 32,083 0 0 32,083 3,840 (495)	(345) 22,923 0 0 22,923 2,923 3,840 (345)	(200) 17,302 0 0 17,302 17,302 3,840 (200)	(144) 10,351 0 0 10,351 3,840 (144)
057 058 059 060 061 062 063 064 065 066 067 068	(375) (375) 4,280 222 222 4,502 3,536	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure Capital Grants (line 8.102) Total Indirect Capital Expenditure Total Indirect Capital Expenditure Total Indirect Capital Expenditure Capital Receipts	(540) (540) 9,818 369 369 10,187	(495) 32,083 0 0 32,083 3,840	(345) 22,923 0 0 22,923 3,840	(200) 17,302 0 0 17,302 17,302 3,840	(144) 10,351 0 0 10,351 3,840
057 058 059 060 061 062 063 064 065 066 067 068 069 070 071	(375) (375) 4,280 222 222 4,502 3,536 (375) 1,127	Capital Receipts Other capital grants received Asset sale proceeds (net book value) (from line 8.111) Other Total Capital Receipts Total Net Direct Capital Expenditure (line 8.057 plus line 8.061) Indirect Capital Expenditure Capital Grants (line 8.102) Total Indirect Capital Expenditure Total Net Capital Expenditure (line 8.062 plus line 8.067) Capital Resource Limit (CRL) SGHSCD formula allocation Asset sale proceeds reapplied (net book value) Project specific funding	(540) (540) 9,818 369 369 10,187 3,840 (540)	(495) 32,083 0 0 32,083 3,840 (495)	(345) 22,923 0 0 22,923 2,923 3,840 (345)	(200) 17,302 0 0 17,302 17,302 3,840 (200)	(144) 10,351 0 0 10,351 3,840 (144) 4,000

1							
8.077	0	Saving / (Excess) against CRL	0	0	0	0	0

		Revenue Finance - NPD / hub Asset Ad	ditions				
[2014-15 £000s	Revenue Finance - NPD / hub Asset Additions	2015-16 £000s	2016-17 £000s	2017-18 £000s	2018-19 £000s	2019-20 £000s
8.078	27,996		80,990	183,713	212,613		
8.079							
8.080							
8.081							
8.082							
8.083							
8.084							
8.085	27,996	Total Revenue Finance - NPD / hub Asset Additions	80,990	183,713	212,613	0	0
-							

-		External Funding Commitments					
ſ	2014-15 £000s	Payments	2015-16 £000s	2016-17 £000s	2017-18 £000s	2018-19 £000s	2019-20 £000s
86		Existing PPP unitary charges	2,000	1,945	1,883	2,040	2,314
87	10,837	Proposed PPP unitary charges	19,733	19,834	19,937	20,043	20,152
88	0	Proposed hub initiative unitary payments	0	0	0	0	0
89	0	Finance leases	0	0	0	0	0
90	0	Operating leases	0	0	0	0	0
91	10,837	Total	21,733	21,779	21,820	22,083	22,466

		Memorandum					
Г	2014-15	1	2015-16	2016-17	2017-18	2018-19	2019-2
	£000s	Capital Grants	£000s	£000s	£000s	£000s	£000s
92	222	Acute Services Redevelopment - D&G Council	369				
33							
94							
95							
96							
97							
98							
99							
00							
01							
02	222	Total (copied to lines 7.01 and 8.063)	369	0	0	0	0
-							
	2014-15		2015-16	2016-17	2017-18	2018-19	2019-2
ŀ	£000s	Source of capital receipts (please enter all figures as negative)	£000s	£000s	£000s	£000s	£000s
03	(375)	Huntingdon (Netherlea £375K 2014-15)	(280)			4'	4
04		Maryfield Lodge	(80)			//	
05		Cameron House	(90)			()	
06		Annan 19 Bank Street	(90)				
07		Garrick		(150)		L	4
08		Annan Charles Street Clinic		(120)		4	
09		Cromarty		(225)			
110		Ladyfield East,Ladyfield West,Artesian well & Maidenbower			(345)	(200)	(144)
111	(375)	Total (copy to line 8.059)	(540)	(495)	(345)	(200)	(144)
r				<u> </u>			
	2014-15		2015-16	2016-17	2017-18	2018-19	2019-2
ŀ	£000s	Donated assets	£000s	£000s	£000s	£000s	£000
112	(400)	Donated assets additions - income	(400)	(400)	(400)	(400)	(400
13	400	Donated assets additions - expenditure	400	400	400	400	400
Г	2014-15		2015-16	2016-17	2017-18	2018-19	2019-3
	£000s	Property	£000s	£000s	£000s	£000s	£000£
F		PFI reversionary interest for projects signed prior to 1 April 2009					1